Phase III CROWN trial of lorlatinib as first-line treatment of ALK-Positive lung cancer meets primary endpoint at an interim analysis

Phase 3, randomised, open-label, parallel 2-arm study in 296 people with previously untreated advanced ALK-positive non-small cell lung cancer met its primary endpoint by demonstrating significantly improved progression-free survival as compared to crizotinib.

SPS commentary:

Currently, lorlatinib is licensed for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.

Biospace Inc.